Premium
Potential small‐molecule drugs as available weapons to fight novel coronavirus ( 2019‐nCoV ): A review
Author(s) -
Rahimkhoei Vahid,
Jabbari Nassrollah,
Nourani Aynaz,
Sharifi Sina,
Akbari Ali
Publication year - 2021
Publication title -
cell biochemistry and function
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.933
H-Index - 61
eISSN - 1099-0844
pISSN - 0263-6484
DOI - 10.1002/cbf.3576
Subject(s) - covid-19 , coronavirus , medicine , pneumonia , monoclonal antibody , drug , virology , betacoronavirus , severe acute respiratory syndrome coronavirus , atypical pneumonia , coronavirus infections , intensive care medicine , immunology , pharmacology , antibody , outbreak , infectious disease (medical specialty) , disease
Since the new coronavirus known as 2019‐nCoV (severe acute respiratory syndrome coronavirus 2, SARS‐CoV‐2) has widely spread in Wuhan, China, with severe pneumonia, scientists and physicians have made remarkable efforts to use various options such as monoclonal antibodies, peptides, vaccines, small‐molecule drugs and interferon therapies to control, prevent or treatment infections of 2019‐nCoV. However, no vaccine or drug has yet been confirmed to completely treat 2019‐nCoV. In this review, we focus on the use of potential available small‐molecule drug candidates for treating infections caused by 2019‐nCoV.